Two-level modeling approach to identify the regulatory dynamics capturing drug response heterogeneity in single-cells

Autor: Madalena Chaves, Luis C. Gomes-Pereira, Jérémie Roux

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)

Abstract Single-cell multimodal technologies reveal the scales of cellular heterogeneity impairing cancer treatment, yet cell response dynamics remain largely underused to decipher the mechanisms of drug resistance they take part in. As the phenotypi

Externí odkaz: https://doaj.org/article/9fa5a24dec424b0e9ffb9978e6e36deb

Gene prioritization based on random walks with restarts and absorbing states, to define gene sets regulating drug pharmacodynamics from single-cell analyses.

Autor: Augusto Sales de Queiroz, Guilherme Sales Santa Cruz, Alain Jean-Marie, Dorian Mazauric, Jérémie Roux, Frédéric Cazals

Publikováno v: PLoS ONE, Vol 17, Iss 11, p e0268956 (2022)

Prioritizing genes for their role in drug sensitivity, is an important step in understanding drugs mechanisms of action and discovering new molecular targets for co-treatment. To formalize this problem, we consider two sets of genes X and P respectiv

Externí odkaz: https://doaj.org/article/8b9205bdc6f44d73b55619f2ed0a463d

Bi-specific molecule against EGFR and death receptors simultaneously targets proliferation and death pathways in tumors

Autor: Yanni Zhu, Nicole Bassoff, Clemens Reinshagen, Deepak Bhere, Michal O. Nowicki, Sean E. Lawler, Jérémie Roux, Khalid Shah

Publikováno v: Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)

Abstract Developing therapeutics that target multiple receptor signaling pathways in tumors is critical as therapies targeting single specific biomarker/pathway have shown limited efficacy in patients with cancer. In this study, we extensively charac

Externí odkaz: https://doaj.org/article/2012dc1702134a00bc4fa931d84efa4f

TRAIL receptor-induced features of epithelial-to-mesenchymal transition increase tumour phenotypic heterogeneity: potential cell survival mechanisms

Autor: Mickael Meyer, Ludovic Peyre, Paul Hofman, Jérémie Roux

Publikováno v: British Journal of Cancer
British Journal of Cancer, 2020, ⟨10.1038/s41416-020-01177-w⟩
British Journal of Cancer, Cancer Research UK, 2020, ⟨10.1038/s41416-020-01177-w⟩

The continuing efforts to exploit the death receptor agonists, such as the tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), for cancer therapy, have largely been impaired by the anti-apoptotic and pro-survival signalling pathwa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a4243552a76acc92de7a0cb7294b16
https://doi.org/10.1038/s41416-020-01177-w

Processing body dynamics drive non-genetic MEK inhibitors tolerance by fine-tuning KRAS and NRAS translation

Autor: Olivia Vidal-Cruchez, Victoria J Nicolini, Tifenn Rete, Roger Rezzonico, Caroline Lacoux, Julien Fassy, Karine Jacquet, Marie-Angela Domdom, Chloé Ventujol, Thierry Juhel, Barnabé Roméo, Jérémie Roux, Arnaud Hubstenberger, Bernard Mari, Baharia Mograbi, Paul Hofman, Patrick Brest

Overactivation of the Mitogen-activated protein kinase (MAPK) pathway is a critical driver of many human cancers. However, therapies targeting this pathway have proven effective in only a few cancers, as cancers inevitably develop resistance. Puzzlin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fbbcd54506d2add4ea64400c4886fc52
https://doi.org/10.1101/2021.12.06.471470